Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF

AIMS: The angiotensin receptor‐neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val) demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all‐cause mortality in patients with ambulatory heart failure and reduced ejection fraction (HFrEF), in particular when...

Descripción completa

Detalles Bibliográficos
Autores principales: Visco, Valeria, Radano, Ilaria, Campanile, Alfonso, Ravera, Amelia, Silverio, Angelo, Masarone, Daniele, Pacileo, Giuseppe, Correale, Michele, Mazzeo, Pietro, Dattilo, Giuseppe, Giallauria, Francesco, Cuomo, Alessandra, Mercurio, Valentina, Tocchetti, Carlo Gabriele, Di Pietro, Paola, Carrizzo, Albino, Citro, Rodolfo, Galasso, Gennaro, Vecchione, Carmine, Ciccarelli, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715790/
https://www.ncbi.nlm.nih.gov/pubmed/35702942
http://dx.doi.org/10.1002/ehf2.13982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715790/
https://www.ncbi.nlm.nih.gov/pubmed/35702942
http://dx.doi.org/10.1002/ehf2.13982

Ejemplares similares